Cerapedics Expands PearlMatrix Access via Vizient Deal

Westminster, Colorado | April 24, 2026

Cerapedics has announced a strategic supplier agreement with Vizient, significantly expanding access to its PearlMatrix® P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product designed for spinal fusion procedures in patients with degenerative disc disease (DDD). This agreement represents a major step toward broadening the availability of advanced bone regeneration technologies across hospitals, academic medical centers, and integrated healthcare networks in the United States.

PearlMatrix Drives Innovation in Bone Regeneration

At the core of this agreement is PearlMatrix®, the first and only bone growth accelerator clinically proven to enhance lumbar spinal fusion, powered by the proprietary P-15 Osteogenic Cell Binding Peptide. This peptide mimics a naturally occurring sequence in Type-1 collagen, enabling rapid attachment and activation of osteogenic cells, which are critical for new bone formation and tissue regeneration.

The product is FDA-approved for multiple lumbar interbody fusion procedures, including ALIF, TLIF, PLIF, OLIF, and LLIF, and is compatible with PEEK and titanium-based spinal implants. Clinical evidence from the ASPIRE TLIF Investigational Device Exemption (IDE) study demonstrated that PearlMatrix achieved more than double the fusion rates at six months compared to traditional autograft methods, highlighting its superior efficacy and accelerated healing potential.

Importantly, PearlMatrix has shown effectiveness even in high-risk patient populations, including individuals with obesity (BMI ≥30), nicotine use, and type 2 diabetes, making it a versatile and clinically valuable solution in complex surgical scenarios. These capabilities position PearlMatrix as a transformative advancement in orthopedic and spinal surgery, where achieving reliable bone fusion remains a key challenge.

Strategic Agreement Enhances Market Reach and Accessibility

The partnership with Vizient significantly enhances the distribution and adoption of Cerapedics’ peptide-powered product portfolio, providing access to over 65% of U.S. acute care providers, including 97% of academic medical centers. This expanded reach is expected to accelerate the adoption of advanced bone graft technologies, while also delivering cost efficiencies and value-based care benefits to healthcare institutions.

Through this agreement, healthcare providers will gain improved access to innovative, clinically validated solutions that can enhance patient outcomes while optimizing healthcare economics. The inclusion of PearlMatrix within Vizient’s network also strengthens Cerapedics’ broader portfolio, which includes i-FACTOR® Bone Graft, further reinforcing its presence in the spinal fusion and orthopedic device market.

This collaboration reflects a growing industry focus on strategic partnerships that integrate innovation with scalable distribution, ensuring that cutting-edge medical technologies reach patients more efficiently and effectively.

Advancing the Future of Spinal Fusion and MedTech Innovation

The agreement underscores Cerapedics’ commitment to redefining bone repair through biologically driven solutions, combining biotechnology and medical device engineering to improve surgical outcomes. As the demand for spinal fusion procedures continues to rise globally, driven by aging populations and increasing prevalence of degenerative spine conditions, the need for faster, safer, and more reliable bone healing technologies is becoming increasingly critical.

PearlMatrix’s unique mechanism of action, which activates natural cellular pathways rather than relying solely on structural support, represents a paradigm shift in regenerative medicine and orthopedic care. By enabling enhanced bone growth through natural biological processes, the product aligns with the broader trend toward patient-centric, minimally invasive, and outcome-driven healthcare solutions.

Looking ahead, the expanded access facilitated by this agreement is expected to drive wider clinical adoption, support ongoing innovation in peptide-based regenerative therapies, and ultimately improve patient quality of life. As healthcare systems continue to prioritize efficiency, safety, and long-term outcomes, technologies like PearlMatrix are poised to play a central role in shaping the future of spinal surgery and regenerative MedTech.

Source: Cerapedics press release